Free tool
FAERS Monitor: Ycanth
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212905 or its brand name (Ycanth, Cantharidin). Reports on generic versions are filed under their own applications.
Reports
183
Serious
33
18% of reports
Hospitalization
9
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- application site vesicles78
- application site pain53
- blister30
- pain16
- application site burn12
- blister rupture8
- hypersensitivity8
- application site erythema7
- drug ineffective7
- accidental exposure to product6
- chemical burn6
- wrong technique in product usage process6
- blood blister5
- product use issue5
- pyrexia5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 5 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 9 |
| 2024 | 58 |
| 2025 | 59 |
| 2026 | 46 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,976 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site vesiclesSignal | 78 | 1399.1 | 1180.5 | 106,320 |
| blister ruptureSignal | 8 | 1253.9 | 634.3 | 8,707 |
| chemical burnSignal | 6 | 601.8 | 273.4 | 3,008 |
| application site burnSignal | 12 | 280.7 | 162.3 | 3,063 |
| application site painSignal | 53 | 277.2 | 220.8 | 14,292 |
| blood blisterSignal | 5 | 184.2 | 77.5 | 736 |
| blisterSignal | 30 | 61.4 | 44.3 | 1,727 |
| application site erythemaSignal | 7 | 30.7 | 14.8 | 173 |
| accidental exposure to productSignal | 6 | 6.7 | 3.0 | 24 |
| hypersensitivitySignal | 8 | 5.0 | 2.5 | 22 |
| wrong technique in product usage processSignal | 6 | 3.4 | 1.5 | 8 |
| product use issueSignal | 5 | 3.1 | 1.3 | 5 |
| painSignal | 16 | 3.0 | 1.9 | 20 |
| pyrexia | 5 | 1.7 | 0.7 | 1 |
| drug ineffective | 7 | 0.6 | 0.3 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.